Company: SGBAF
Filing Date: 2025-04-23
Form Type: DRS/A
Source: 0000950123-25-003652
Chunk: 16

Company: SES S.A.
Filing Date: 2025-04-23
Form: DRS/A
Chunk 16
---
 following the Closing as part of the Liquidation. The Closing

8

Confidential Treatment Requested by SES

Pursuant to 17 C.F.R. Section 200.83

Cash Consideration distributable to Intelsat’s shareholders (including holders of Intelsat’s vested RSUs and PSUs) will be reduced by the $500 million distribution out of
Intelsat’s share premium to Intelsat shareholders on September 27, 2024, and amounts payable in respect of Intelsat’s outstanding warrants, which will expire, terminate and become void at the Closing and represent only the right to receive
the “Black-Scholes” value of the outstanding Intelsat warrants, which value will be determined by a third-party valuation firm in accordance with the applicable warrant agreements and paid to the holders of Intelsat warrants in cash. In
addition, a portion of the Closing Cash Consideration will be held back for the duration of the Liquidation to satisfy any remaining liabilities of Intelsat and to cover the costs of winding up the affairs of Intelsat. Once the Liquidation has
been completed, any remaining Closing Cash Consideration held by Intelsat will be distributed to Intelsat’s shareholders (including holders of Intelsat’s vested RSUs and PSUs).

Q: Who can help answer my questions?

A: If you are an Intelsat shareholder and would like a copy of this prospectus, or if you have questions about the Acquisition or the
other matters discussed in this prospectus, you should contact:

Intelsat S.A.

7900 Tysons One Place

McLean, VA 22102

Attn: Investor Relations

Tel: (703) 559-6800

Q: Where can I find more information about SES and Intelsat?

A:You can find more information about SES and Intelsat from the various sources described under “Where You Can Find More Information” beginning on page 225 of this prospectus.

9

Confidential Treatment Requested by SES

Pursuant to 17 C.F.R. Section 200.83

SUMMARY

This summary highlights selected information from this prospectus. It may not contain all the information that is important to you. Accordingly, we urge you to read this prospectus carefully and in its entirety, including the Annexes hereto, the documents incorporated herein by reference, the registration statement to which this prospectus relates, and all other documents attached to or incorporated into this